Angela Isabel Maldonado-Restrepo, Gabriel E Acelas-Gonzalez, Gabriel-Santiago Rodríguez-Vargas, Pedro Rodriguez-Linares, Javier-Leonardo Gonzalez-Rodriguez, Adriana Rojas-Villarraga, Pedro Santos-Moreno
{"title":"Comprehensive Insights into the Economic Burden of Rheumatoid Arthritis in Latin America: A Systematic Literature Review of Regional Perspectives.","authors":"Angela Isabel Maldonado-Restrepo, Gabriel E Acelas-Gonzalez, Gabriel-Santiago Rodríguez-Vargas, Pedro Rodriguez-Linares, Javier-Leonardo Gonzalez-Rodriguez, Adriana Rojas-Villarraga, Pedro Santos-Moreno","doi":"10.2147/CEOR.S498994","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Rheumatoid arthritis (RA) affects approximately 0.3 to 1.2% of the world's population. The objective of this study was to identify the existing literature on economic evaluations of RA in Latin America.</p><p><strong>Patients and methods: </strong>Studies of economic evaluations of patients with RA from 2000 to 2023 were analyzed using the databases PubMed, Scopus, Web of Science, Embase, Cochrane, and the Virtual Health Library following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Study quality was assessed using the Joanna Briggs Institute (JBI) tool, and qualitative analysis was done (following SwiM guidelines).</p><p><strong>Results: </strong>A total of 851 articles were identified. Following the application of inclusion criteria to titles and abstracts, 117 articles were initially considered eligible. Of these, 42 were excluded due to population or outcome-based errors, leaving 27 articles and 48 abstracts for analysis. Duplicates were removed prior to this process. The included studies involved various designs: cross-sectional, longitudinal, prospective, and retrospective. Brazil accounted for the highest proportion of publications (33.3%), followed by Colombia and Mexico, each contributing 26%. Most economic studies focused on cost analysis (86%), while cost-effectiveness studies and cost-utility studies represented 7.4% and 3.3%, respectively. Predominant perspectives included third-party payer 26%, insurers 14.8%, social providers 7.4%, and mixed providers 3.7%. In terms of publications of abstracts, Colombia leaded at 35.4%. The predominant perspective was that of the provider 66.6%, including the general perspective (37.5%), private (34.3%), public (22%), and mixed (6.2%) and the perspective of third-party payers (33.3%).</p><p><strong>Conclusion: </strong>Economic evaluations of rheumatoid arthritis in Latin America remain limited, with most studies focusing on cost analysis. Brazil, Colombia, and Mexico lead in publications, primarily from a provider perspective. Greater emphasis on cost-effectiveness and broader economic evaluations is needed to guide health policy in the region.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"17 ","pages":"349-373"},"PeriodicalIF":2.1000,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12011030/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ClinicoEconomics and Outcomes Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/CEOR.S498994","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Rheumatoid arthritis (RA) affects approximately 0.3 to 1.2% of the world's population. The objective of this study was to identify the existing literature on economic evaluations of RA in Latin America.
Patients and methods: Studies of economic evaluations of patients with RA from 2000 to 2023 were analyzed using the databases PubMed, Scopus, Web of Science, Embase, Cochrane, and the Virtual Health Library following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Study quality was assessed using the Joanna Briggs Institute (JBI) tool, and qualitative analysis was done (following SwiM guidelines).
Results: A total of 851 articles were identified. Following the application of inclusion criteria to titles and abstracts, 117 articles were initially considered eligible. Of these, 42 were excluded due to population or outcome-based errors, leaving 27 articles and 48 abstracts for analysis. Duplicates were removed prior to this process. The included studies involved various designs: cross-sectional, longitudinal, prospective, and retrospective. Brazil accounted for the highest proportion of publications (33.3%), followed by Colombia and Mexico, each contributing 26%. Most economic studies focused on cost analysis (86%), while cost-effectiveness studies and cost-utility studies represented 7.4% and 3.3%, respectively. Predominant perspectives included third-party payer 26%, insurers 14.8%, social providers 7.4%, and mixed providers 3.7%. In terms of publications of abstracts, Colombia leaded at 35.4%. The predominant perspective was that of the provider 66.6%, including the general perspective (37.5%), private (34.3%), public (22%), and mixed (6.2%) and the perspective of third-party payers (33.3%).
Conclusion: Economic evaluations of rheumatoid arthritis in Latin America remain limited, with most studies focusing on cost analysis. Brazil, Colombia, and Mexico lead in publications, primarily from a provider perspective. Greater emphasis on cost-effectiveness and broader economic evaluations is needed to guide health policy in the region.
目的:类风湿关节炎(RA)影响约0.3%至1.2%的世界人口。本研究的目的是确定现有文献对拉丁美洲RA的经济评价。患者和方法:使用PubMed、Scopus、Web of Science、Embase、Cochrane和虚拟健康图书馆等数据库,按照系统评价和荟萃分析(PRISMA)指南的首选报告项目,对2000年至2023年RA患者的经济评估研究进行分析。使用Joanna Briggs Institute (JBI)工具评估研究质量,并进行定性分析(遵循SwiM指南)。结果:共鉴定出851篇文献。在将纳入标准应用于标题和摘要之后,117篇文章最初被认为符合条件。其中42篇由于总体或结果错误而被排除,留下27篇文章和48篇摘要供分析。在此过程之前已删除重复项。纳入的研究包括各种设计:横断面、纵向、前瞻性和回顾性。巴西的出版物占比最高(33.3%),其次是哥伦比亚和墨西哥,各占26%。大多数经济研究侧重于成本分析(86%),而成本效益研究和成本效用研究分别占7.4%和3.3%。主要观点包括第三方付款人26%,保险公司14.8%,社会提供者7.4%,混合提供者3.7%。就摘要发表量而言,哥伦比亚以35.4%领先。占主导地位的视角为提供者视角(66.6%),包括一般视角(37.5%)、私人视角(34.3%)、公共视角(22%)、混合视角(6.2%)和第三方支付者视角(33.3%)。结论:拉丁美洲类风湿关节炎的经济评价仍然有限,大多数研究集中在成本分析上。主要从提供者的角度来看,巴西、哥伦比亚和墨西哥在出版物方面领先。需要更加强调成本效益和更广泛的经济评价,以指导该区域的卫生政策。